Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
18 Junio 2024 - 6:30AM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced oral presentations on pemvidutide, an
investigational GLP-1/glucagon dual receptor agonist in development
for the treatment of obesity and MASH, at the American Diabetes
Association’s (ADA) 84th Scientific Sessions, to be held in
Orlando, FL from June 21-24, 2024.
Details for the oral presentations are as
follows:
Session Title: |
Leveling Up Incretin-Based Therapy in Type 2 Diabetes |
Session Date/Time: |
Saturday, June 22, 2024, 4:30 PM - 6:00 PM |
Presentation Title: |
Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on
Cardioinflammatory Lipids |
Presenter: |
John J. Suschak, Ph.D., Senior Director, Translational Science,
Altimmune |
Presentation Date/Time: |
Saturday, June 22, 2024 at 4:45 pm EDT |
Session Title: |
Weighing Opportunities of Incretin-Based Therapy in Obesity |
Session Date/Time: |
Sunday, June 23, 2024, 1:30pm - 3:00pm |
Presentation Title: |
Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects
with Overweight or Obesity –A 48-Week, Placebo-Controlled, Phase 2
(MOMENTUM) Trial |
Presenter: |
Louis Aronne, M.D., Professor of Metabolic Research and Professor
of Clinical Medicine, Weil Cornell Medical School |
Presentation Date/Time: |
Sunday, June 23, 2024 at 1:45 pm EDT |
The presentation by Dr. Aronne will also be
featured in the official Press Program for the American Diabetes
Association’s 84th Scientific Sessions.
These presentations will be accessible on the
Events section of the Altimmune website.
About PemvidutidePemvidutide is
a novel, investigational, peptide-based GLP-1/glucagon dual
receptor agonist in development for the treatment of obesity and
Metabolic Dysfunction-Associated Steatohepatitis (MASH). Activation
of the GLP-1 and glucagon receptors is believed to mimic the
complementary effects of diet and exercise on weight loss, with
GLP-1 suppressing appetite and glucagon increasing energy
expenditure. Glucagon is also recognized as having direct effects
on hepatic fat metabolism, which is believed to lead to rapid
reductions in levels of liver fat and serum lipids. In clinical
trials to date, once-weekly pemvidutide has demonstrated compelling
weight loss, robust reductions in triglycerides, LDL cholesterol,
liver fat content and blood pressure. The U.S. FDA has granted Fast
Track designation to pemvidutide for the treatment of MASH.
Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial
and is being studied in the ongoing IMPACT Phase 2b MASH trial.
About AltimmuneAltimmune is a clinical-stage
biopharmaceutical company focused on developing innovative
next-generation peptide-based therapeutics. The Company is
developing pemvidutide, a GLP-1/glucagon dual receptor agonist for
the treatment of obesity and MASH. For more information, please
visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Company Contact: Richard EisenstadtChief
Financial OfficerPhone: 240-654-1450ir@altimmune.com
Investor Contacts: Lee Roth Burns
McClellan Phone: 646-382-3403 lroth@burnsmc.com
Julia Weilman Burns McClellan Phone:
646-732-4443 jweilman@burnsmc.com
Media Contact: Danielle Cantey Inizio
Evoke, Biotech Phone:
619-826-4657 Danielle.cantey@inizioevoke.com
Altimmune (NASDAQ:ALT)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Altimmune (NASDAQ:ALT)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024